Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

BUY
$1.51 - $2.29 $15,462 - $23,449
10,240 New
10,240 $17,000
Q1 2018

May 16, 2018

SELL
$8.99 - $14.95 $139,632 - $232,203
-15,532 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$8.26 - $16.76 $128,294 - $260,316
15,532
15,532 $230,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $365M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Alpine Global Management, LLC Portfolio

Follow Alpine Global Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpine Global Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpine Global Management, LLC with notifications on news.